Tearsheet

Teladoc Health (TDOC)


Market Price (5/11/2026): $7.22 | Market Cap: $43.1 Mil
Sector: Health Care | Industry: Health Care Technology

Teladoc Health (TDOC)


Market Price (5/11/2026): $7.22
Market Cap: $43.1 Mil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%

Attractive yield
FCF Yield is 293%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -88%, 3Y Excs Rtn is -153%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -157 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.3%

Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 664%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.5%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.7%, Rev Chg QQuarterly Revenue Change % is -2.5%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -400%

Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 498%

Key risks
TDOC key risks include [1] significant underperformance and profitability challenges within its BetterHelp segment and [2] intense competition from large tech and retail entrants threatening its market share.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%
1 Attractive yield
FCF Yield is 293%
2 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -88%, 3Y Excs Rtn is -153%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -157 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.3%
5 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 664%
6 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.5%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.7%, Rev Chg QQuarterly Revenue Change % is -2.5%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -400%
8 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 498%
9 Key risks
TDOC key risks include [1] significant underperformance and profitability challenges within its BetterHelp segment and [2] intense competition from large tech and retail entrants threatening its market share.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Teladoc Health (TDOC) stock has gained about 35% since 1/31/2026 because of the following key factors:

1. Stronger-than-expected Fourth Quarter 2025 Earnings and Positive 2026 Outlook.

Teladoc Health reported its fourth quarter 2025 results on February 25, 2026, with a narrower net loss of $0.14 per share, significantly better than the $0.28 per share loss in Q4 2024 and surpassing the consensus estimate of a $0.19 loss per share. Consolidated revenue for Q4 reached $642.3 million. Notably, the Integrated Care segment saw a 5% increase in revenue to $409.1 million and a 23% rise in adjusted EBITDA to $65 million. The company also provided full-year 2026 guidance, projecting consolidated revenue between $2.47 billion and $2.59 billion, and adjusted EBITDA from $266 million to $308 million, indicating a 2% year-over-year growth at the midpoint for adjusted EBITDA. This positive earnings report contributed to a 5.92% gain in the stock price on the day of the announcement.

2. Favorable Regulatory Environment with Extended Telehealth Flexibilities.

A federal funding bill signed by President Trump on February 3, 2026, which was announced on February 5, 2026, extended crucial telehealth provisions for several years. These extensions included Medicare telehealth flexibilities until December 31, 2027, and a five-year extension for the Acute Hospital Care at Home Program through September 30, 2030. This legislative action provided increased regulatory certainty and stability for Teladoc Health and the broader telehealth industry.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 33.0% change in TDOC stock from 1/31/2026 to 5/10/2026 was primarily driven by a 35.4% change in the company's P/S Multiple.
(LTM values as of)13120265102026Change
Stock Price ($)5.457.2533.0%
Change Contribution By: 
Total Revenues ($ Mil)2,5282,514-0.5%
P/S Multiple0.00.035.4%
Shares Outstanding (Mil)66-1.2%
Cumulative Contribution33.0%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/10/2026
ReturnCorrelation
TDOC33.0% 
Market (SPY)3.6%38.7%
Sector (XLV)-6.9%13.3%

Fundamental Drivers

The -16.0% change in TDOC stock from 10/31/2025 to 5/10/2026 was primarily driven by a -14.5% change in the company's P/S Multiple.
(LTM values as of)103120255102026Change
Stock Price ($)8.637.25-16.0%
Change Contribution By: 
Total Revenues ($ Mil)2,5282,514-0.5%
P/S Multiple0.00.0-14.5%
Shares Outstanding (Mil)66-1.2%
Cumulative Contribution-16.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/10/2026
ReturnCorrelation
TDOC-16.0% 
Market (SPY)5.5%42.1%
Sector (XLV)0.3%16.9%

Fundamental Drivers

The 0.8% change in TDOC stock from 4/30/2025 to 5/10/2026 was primarily driven by a 6.8% change in the company's P/S Multiple.
(LTM values as of)43020255102026Change
Stock Price ($)7.197.250.8%
Change Contribution By: 
Total Revenues ($ Mil)2,5702,514-2.1%
P/S Multiple0.00.06.8%
Shares Outstanding (Mil)66-3.5%
Cumulative Contribution0.8%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2025 to 5/10/2026
ReturnCorrelation
TDOC0.8% 
Market (SPY)30.4%42.4%
Sector (XLV)4.0%24.6%

Fundamental Drivers

The -72.7% change in TDOC stock from 4/30/2023 to 5/10/2026 was primarily driven by a -71.1% change in the company's P/S Multiple.
(LTM values as of)43020235102026Change
Stock Price ($)26.537.25-72.7%
Change Contribution By: 
Total Revenues ($ Mil)2,4072,5144.5%
P/S Multiple0.10.0-71.1%
Shares Outstanding (Mil)56-9.5%
Cumulative Contribution-72.7%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2023 to 5/10/2026
ReturnCorrelation
TDOC-72.7% 
Market (SPY)78.7%40.0%
Sector (XLV)13.0%28.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
TDOC Return-54%-74%-9%-58%-23%-1%-97%
Peers Return-16%-29%9%38%15%5%8%
S&P 500 Return27%-19%24%23%16%7%95%

Monthly Win Rates [3]
TDOC Win Rate25%25%50%25%33%60% 
Peers Win Rate39%37%52%57%45%52% 
S&P 500 Win Rate75%42%67%75%67%60% 

Max Drawdowns [4]
TDOC Max Drawdown-56%-75%-34%-68%-28%-36% 
Peers Max Drawdown-32%-45%-29%-31%-18%-29% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMWL, HIMS, DOCS, CVS, AMZN. See TDOC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)

How Low Can It Go

EventTDOCS&P 500
2024 Yen Carry Trade Unwind
  % Loss-24.1%-7.8%
  % Gain to Breakeven31.8%8.5%
  Time to Breakeven34 days18 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-46.3%-19.2%
  % Gain to Breakeven86.3%23.7%
  Time to Breakeven315 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-17.7%-3.7%
  % Gain to Breakeven21.5%3.9%
  Time to Breakeven27 days6 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-63.6%-12.2%
  % Gain to Breakeven174.5%13.9%
  Time to Breakeven419 days62 days
2014-2016 Oil Price Collapse
  % Loss-58.4%-6.8%
  % Gain to Breakeven140.3%7.3%
  Time to Breakeven455 days15 days

Compare to AMWL, HIMS, DOCS, CVS, AMZN

In The Past

Teladoc Health's stock fell -24.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 31.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventTDOCS&P 500
2024 Yen Carry Trade Unwind
  % Loss-24.1%-7.8%
  % Gain to Breakeven31.8%8.5%
  Time to Breakeven34 days18 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-46.3%-19.2%
  % Gain to Breakeven86.3%23.7%
  Time to Breakeven315 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-63.6%-12.2%
  % Gain to Breakeven174.5%13.9%
  Time to Breakeven419 days62 days
2014-2016 Oil Price Collapse
  % Loss-58.4%-6.8%
  % Gain to Breakeven140.3%7.3%
  Time to Breakeven455 days15 days

Compare to AMWL, HIMS, DOCS, CVS, AMZN

In The Past

Teladoc Health's stock fell -24.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 31.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Teladoc Health (TDOC)

Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.

AI Analysis | Feedback

Here are 1-3 brief analogies for Teladoc Health:

  • Amazon for healthcare

  • Uber for doctor visits

AI Analysis | Feedback

  • Primary and Specialty Care Telehealth Solutions: Provides virtual consultations with doctors for general health concerns and specialized medical conditions.
  • Chronic Condition Management: Offers digital programs and support for individuals managing chronic illnesses such as diabetes, hypertension, and heart failure.
  • Expert Medical Services: Connects members with top medical experts for second opinions, complex diagnoses, and treatment plan guidance.
  • Mental Health Solutions: Delivers virtual therapy, psychiatry, and mental wellness programs to address a range of behavioral health needs.
  • Platform and Program Services: Provides the underlying technology platform and comprehensive program management for clients to offer virtual care to their members.

AI Analysis | Feedback

Teladoc Health (TDOC) serves a diverse range of major customers, primarily other companies, as well as individual members. Based on the provided background information, its major customer segments include:

  • Employers
  • Health plans
  • Hospitals and health systems
  • Insurance and financial services companies
  • Individual members

The background information describes categories of customers rather than listing specific company names or their stock symbols.

AI Analysis | Feedback

Major Suppliers:

  • Amazon (AMZN)

AI Analysis | Feedback

Chuck Divita, III Chief Executive Officer

Chuck Divita, III was appointed CEO of Teladoc Health in June 2024. Prior to this, he held senior leadership positions at GuideWell, a large health solutions organization that includes Florida Blue, where he served as Executive Vice President for Commercial Markets and Chief Financial Officer. Before joining GuideWell, Mr. Divita was the Chief Financial Officer of FPIC Insurance Group, a publicly traded property and casualty insurer. He has a reputation as an innovative, results-driven leader in the healthcare industry, recognized for driving growth and advancing new healthcare models. He has also served on the boards of various healthcare companies, including Prime Therapeutics, Availity, and VIM.

Mala Murthy Chief Financial Officer

Mala Murthy has served as the CFO of Teladoc Health since June 2019. She also served as acting Chief Executive Officer from April to June 2024. Before joining Teladoc Health, Ms. Murthy held several senior executive positions at American Express, including Chief Financial Officer of the Global Commercial Services segment. Prior to American Express, she held various leadership positions with PepsiCo, where she notably led high-growth business units and oversaw financial planning and analysis, corporate and international treasury, and corporate strategy. She has a proven track record of supporting multi-billion-dollar acquisitions and developing capital structure and liquidity strategies.

Dr. Vidya Raman-Tangella Chief Medical Officer

Dr. Vidya Raman-Tangella was named Chief Medical Officer of Teladoc Health in April 2022. In this role, she leads the company's enterprise clinical strategy, quality, and research efforts, with a focus on areas such as health equity and clinical evidence. Before joining Teladoc Health, Dr. Raman-Tangella was the general manager of Healthcare and Life Sciences Solutions at AWS (Amazon Web Services), where she developed strategies and solutions for the healthcare ecosystem. Her career includes leadership roles at prominent healthcare companies such as Blue Cross Blue Shield, Johnson & Johnson, and UnitedHealthcare, where she focused on designing integrated health and wellness solutions for employers and health plans. Her expertise lies in leveraging science, data, technology, and partnerships to create healthcare solutions for disease prevention, personalized patient experiences, and healthcare access.

Carlos Nueno President, International

Carlos Nueno is the President of International operations for Teladoc Health, a role he has held since July 2018. He is responsible for the strategic direction, operations, and client management of Teladoc Health's global footprint. Mr. Nueno co-founded and served as CEO of Advance Medical from 1999 to 2018, leading its growth to become a global provider of health services with over 900 employees across North America, Europe, and Asia. Advance Medical was acquired by Teladoc Health in 2018. Earlier in his career, he worked as a consultant for Gemini Consulting.

Kelly Bliss President, U.S. Group Health

Kelly Bliss is the President of Teladoc Health's U.S. Group Health business. She is responsible for overseeing strategy, partnerships, product management, marketing, sales, operations, and client management for virtual care services that reach over 100 million covered Americans. Prior to this role, Ms. Bliss served as Teladoc's Chief Client Officer from 2017 to 2020, where she was instrumental in achieving record client satisfaction and retention through a focus on delivering value and a best-in-class experience. She also played a key role in the integration efforts of several acquisitions, including the integration of Best Doctors after its acquisition by Teladoc Health in 2017, where she had previously served as Chief of Staff. Additionally, she contributed to integrating Livongo's chronic care management solutions after its acquisition by Teladoc Health. Ms. Bliss has built and managed high-performing global teams at companies such as Best Doctors and InterSystems.

AI Analysis | Feedback

The key risks to Teladoc Health (TDOC) primarily revolve around intense market competition, ongoing struggles with its BetterHelp segment impacting overall profitability, and the lasting repercussions of its significant acquisitions.

  1. Intense Competition and Profitability Challenges: Teladoc Health operates in a highly competitive virtual healthcare market, facing pressure from traditional healthcare providers, new telehealth entrants, and large technology and retail companies expanding into healthcare. This environment leads to pricing pressure and difficulties in attracting and retaining users. A significant contributor to Teladoc's overall profitability struggles is its BetterHelp segment, which has experienced declining revenue and user numbers due to high customer acquisition costs. This segment's underperformance acts as a drag on the company's growth trajectory and its path to consistent profitability, with analysts not forecasting a full year of profitability until 2025 or later. The company has also recorded recurring goodwill impairment charges, reflecting past acquisitions not living up to their valuations.
  2. Integration and Performance of Acquisitions: A major strategic move, the acquisition of Livongo in 2020, has been cited as a source of significant challenges. Issues included a high acquisition cost, difficulties in integrating the different company cultures and operating models, and a failure to quickly achieve expected synergies. These problems have contributed to substantial goodwill impairment charges and negative investor sentiment. While the company has worked to address these integration issues and a securities lawsuit related to the Livongo integration was dismissed, the ongoing struggles of the BetterHelp segment, which stemmed from this acquisition, continue to pose a risk to Teladoc's financial performance.
  3. Regulatory and Reimbursement Uncertainty: As a provider of virtual healthcare services, Teladoc Health is highly susceptible to changes in healthcare laws, regulations, and reimbursement policies. The regulatory landscape for telehealth is dynamic, and shifts in government or private insurer reimbursement models could significantly impact the accessibility, demand, and profitability of Teladoc's services. The longevity of temporary regulatory changes that expanded telehealth access during the COVID-19 pandemic remains uncertain, requiring Teladoc to adapt to potential reversions that could affect service offerings and revenue.

AI Analysis | Feedback

1. Amazon's expansion into virtual primary care and chronic condition management: With initiatives like Amazon Clinic and the acquisition of One Medical, Amazon is a well-resourced, consumer-centric player directly entering Teladoc's core virtual care markets. Amazon's ability to bundle services, leverage its vast customer base, and utilize its logistics infrastructure poses a significant competitive threat, potentially disrupting established pricing models and customer acquisition strategies.

2. Vertical integration by major health plans and health systems: Large health plans (e.g., UnitedHealth Group's Optum, Cigna's Evernorth with MDLive, CVS Health/Aetna) are increasingly building out their own comprehensive virtual care platforms and directly acquiring or employing providers. Similarly, major health systems are enhancing their in-house telehealth capabilities, often integrating them deeply with their existing services. This trend could reduce their reliance on third-party virtual care providers like Teladoc, leading to increased competition for Teladoc's client base of employers and health plans, and potentially disintermediating Teladoc from parts of the care delivery chain.

AI Analysis | Feedback

Teladoc Health (symbol: TDOC) operates within several substantial addressable markets for its virtual healthcare services and solutions.

Virtual Healthcare Services (Telehealth/Telemedicine)

  • The global telehealth market was estimated at approximately USD 123.26 billion in 2024 and is projected to reach USD 455.27 billion by 2030, growing at a CAGR of 24.68% from 2025 to 2030.
  • Another estimate places the global telehealth market size at USD 126.1 billion in 2024, anticipated to grow to USD 403.2 billion by 2034, at a CAGR of 12.4% from 2025 to 2034.
  • The U.S. telehealth market generated a revenue of USD 42,540.9 million in 2024 and is expected to reach USD 150,131.3 million by 2030, with a CAGR of 23.8% from 2025 to 2030.
  • The U.S. virtual care market was estimated at USD 8.83 billion in 2024 and is expected to grow at a CAGR of 32.35% from 2025 to 2030. Another projection for the U.S. virtual care market indicates a value of USD 12.48 billion in 2025, reaching USD 206.74 billion by 2035 at a CAGR of 32.39% from 2026 to 2035.
  • Teladoc Health has stated its combined total addressable market in the telehealth space is approximately USD 121 billion.

Chronic Condition Management

  • The global chronic disease management market was valued at USD 8.33 billion in 2024 and is expected to reach USD 27.90 billion by 2032, with a CAGR of 16.30% from 2025 to 2032.
  • Another report values the global chronic disease management market at USD 5.82 billion in 2024, projected to increase to USD 20.87 billion by 2034, expanding at a CAGR of 13.62% from 2025 to 2034.
  • The U.S. chronic disease management market size was USD 1.75 billion in 2024 and is projected to be worth around USD 6.38 billion by 2034, growing at a CAGR of 13.80% from 2025 to 2034.

Mental Health Solutions

  • The global mental health market size is forecast to increase by USD 153.3 billion at a CAGR of 6.8% between 2024 and 2029.
  • The mental health apps market globally is projected to reach USD 22.73 billion by 2030, from USD 9.94 billion in 2025, at a CAGR of 18.0% during the forecast period.
  • North America is estimated to contribute 36% to the growth of the global mental health market during the forecast period.

AI Analysis | Feedback

Teladoc Health (TDOC) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market shifts:

  1. Transition to Visit-Oriented Models and Growth in Integrated Care: Teladoc Health is strategically shifting its U.S. virtual care subscriptions from traditional subscription-based models to more visit-oriented models, which are more reflective of the U.S. healthcare fee-for-service construct. While this shift may initially impact subscription revenue, the company anticipates that growth in visit volumes will become a key driver of overall revenue in the long term. The Integrated Care segment, which serves health plans, employers, and health systems, is projected to see revenue growth between 0.4% and 3.9% in 2026, with contributions from recent acquisitions.
  2. Scaling BetterHelp's Insurance Offering: The BetterHelp segment, Teladoc Health's virtual mental health platform, is undergoing a significant transition from a cash-pay model to an in-network, insurance-covered model. This expansion into accepting insurance is identified as a major growth opportunity, with Teladoc Health forecasting BetterHelp's insurance revenue to range from $75 million to $90 million in 2026, with an annualized revenue run rate exceeding $100 million.
  3. International Market Expansion: Teladoc Health is actively pursuing growth in international markets, with expectations for double-digit revenue growth from its international segment in 2026. The company is expanding its presence and establishing partnerships in new regions, including France, Germany, the Netherlands, Spain, and Austria.
  4. New Innovations and AI Advancements in Integrated Care: The company is investing in new innovations and capabilities within its Integrated Care products, particularly through advancements in artificial intelligence. The Pulse platform, for instance, is designed to unify extensive data, apply intelligence, and connect AI-driven insights to patient care, thereby enhancing virtual care offerings and supporting future growth.

AI Analysis | Feedback

Share Repurchases

  • Teladoc Health reported no share repurchases for the trailing twelve months ended September 2025, and $0 million for the three months ended September 2025.

Share Issuance

  • On May 22, 2025, Teladoc Health’s stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6.85 million.
  • In Q4 2025, Teladoc Health had 178 million shares outstanding, representing a 0.5% increase from the prior quarter.
  • The company announced an employee inducement award under NYSE Rule 303A.08 on March 4, 2026, for a new employee.

Outbound Investments

  • In April 2025, Teladoc Health acquired digital mental health company UpLift for $45 million, consisting of $30 million cash and up to $15 million in contingent earnouts, to expand its virtual mental health services.
  • In February 2025, Teladoc Health signed an agreement to acquire virtual preventive care company Catapult Health for $65 million, with an additional $5 million in contingent earnout consideration, aiming to enhance chronic condition management and at-home diagnostic testing.
  • Teladoc Health acquired Telecare, a provider of teleconsultation services, in August 2025.

Capital Expenditures

  • Capital expenditures and capitalized software development costs totaled $127.5 million for the full year 2025, an increase from $124.1 million in 2024.
  • For the first nine months of 2025, capital expenditures and capitalized software development costs were $93.1 million, compared to $94.4 million in the first nine months of 2024.
  • The capital expenditures are focused on necessary investments in the company's platform and technology, product innovation, enhanced cardiometabolic programs, integrated mental health offerings, and international expansion.

Better Bets vs. Teladoc Health (TDOC)

Latest Trefis Analyses

Trade Ideas

Select ideas related to TDOC.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield04302026GEHCGE HealthCare TechnologiesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
IQV_4302026_Dip_Buyer_FCFYield04302026IQVIQVIADip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
UHS_4302026_Dip_Buyer_FCFYield04302026UHSUniversal Health ServicesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
ABT_4302026_Dip_Buyer_ValueBuy04302026ABTAbbott LaboratoriesDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
0.0%0.0%0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K04302026ZBIOZenas BioPharmaInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
0.0%0.0%0.0%
TDOC_4302024_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG04302024TDOCTeladoc HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
-30.0%-43.6%-48.9%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

TDOCAMWLHIMSDOCSCVSAMZNMedian
NameTeladoc .American.Hims & H.Doximity CVS Heal.Amazon.c. 
Mkt Price7.257.9728.2725.9890.55272.6827.12
Mkt Cap0.00.16.44.9115.32,929.45.6
Rev LTM2,5142372,348638407,905742,7762,431
Op Inc LTM-157-9210623911,69185,422172
FCF LTM127-45573077,394-2,47292
FCF 3Y Avg169-1131012347,15821,346201
CFO LTM288-4230031510,332148,531308
CFO 3Y Avg311-1042082409,994120,527276

Growth & Margins

TDOCAMWLHIMSDOCSCVSAMZNMedian
NameTeladoc .American.Hims & H.Doximity CVS Heal.Amazon.c. 
Rev Chg LTM-1.5%-9.3%59.0%15.9%7.6%14.2%10.9%
Rev Chg 3Y Avg0.7%-4.9%64.6%16.7%7.2%12.3%9.8%
Rev Chg Q-2.5%-17.9%28.4%9.8%6.2%16.6%8.0%
QoQ Delta Rev Chg LTM-0.6%-4.8%6.2%2.6%1.5%3.6%2.0%
Op Inc Chg LTM15.8%46.6%70.6%6.9%8.3%19.2%17.5%
Op Inc Chg 3Y Avg11.0%28.1%146.0%26.5%-9.2%108.4%27.3%
Op Mgn LTM-6.3%-38.9%4.5%37.4%2.9%11.5%3.7%
Op Mgn 3Y Avg-7.4%-69.5%1.8%37.6%3.1%10.2%2.4%
QoQ Delta Op Mgn LTM0.2%3.3%-0.7%-2.3%0.3%0.3%0.2%
CFO/Rev LTM11.5%-17.6%12.8%49.5%2.5%20.0%12.1%
CFO/Rev 3Y Avg12.1%-41.1%12.7%42.8%2.6%18.1%12.4%
FCF/Rev LTM5.0%-18.8%2.4%48.2%1.8%-0.3%2.1%
FCF/Rev 3Y Avg6.6%-44.6%7.1%41.6%1.9%3.5%5.1%

Valuation

TDOCAMWLHIMSDOCSCVSAMZNMedian
NameTeladoc .American.Hims & H.Doximity CVS Heal.Amazon.c. 
Mkt Cap0.00.16.44.9115.32,929.45.6
P/S0.00.62.77.60.33.91.6
P/Op Inc-0.3-1.460.820.49.934.315.1
P/EBIT-0.3-1.460.820.417.624.819.0
P/E-0.3-1.550.020.339.332.326.3
P/CFO0.2-3.221.415.411.219.713.3
Total Yield-395.4%-66.5%2.0%4.9%5.5%3.1%2.5%
Dividend Yield0.0%0.0%0.0%0.0%3.0%0.0%0.0%
FCF Yield 3Y Avg338.8%-72.2%2.3%3.0%7.7%1.1%2.7%
D/E24.00.00.20.00.70.10.1
Net D/E6.6-1.30.1-0.10.60.00.1

Returns

TDOCAMWLHIMSDOCSCVSAMZNMedian
NameTeladoc .American.Hims & H.Doximity CVS Heal.Amazon.c. 
1M Rtn42.2%53.6%45.5%23.4%15.1%14.4%32.8%
3M Rtn44.7%79.5%22.8%-6.3%16.6%29.7%26.2%
6M Rtn-3.7%89.3%-31.1%-52.1%16.6%11.6%3.9%
12M Rtn2.0%16.5%-45.6%-56.1%40.2%41.2%9.2%
3Y Rtn-70.8%-81.6%167.5%-21.7%47.5%143.1%12.9%
1M Excs Rtn29.7%38.6%34.7%14.4%7.4%8.3%22.0%
3M Excs Rtn38.0%72.8%16.1%-13.0%9.9%22.9%19.5%
6M Excs Rtn-18.9%65.5%-44.2%-68.3%8.4%0.1%-9.4%
12M Excs Rtn-25.7%-13.8%-77.4%-86.9%9.2%13.1%-19.8%
3Y Excs Rtn-152.7%-162.1%57.5%-106.1%-35.7%82.2%-70.9%

Comparison Analyses

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Integrated Care1,5291,4691,3741,301 
BetterHelp1,0411,1341,020721 
Other 0131125
Access Fees Revenue    847
Visit Fee Revenue    222
Total2,5702,6022,4072,0331,094


Operating Income by Segment
$ Mil20252024202320222021
Integrated Care233192135  
BetterHelp78136114  
Acquisition, integration, and transformation costs-2-21-16  
Depreciation of property and equipment-10-11-11  
Restructuring costs-20-17-7  
Stock-based compensation-146-202-218  
Amortization of intangible assets-363-326-245  
Goodwill impairment-7900-13,403  
Other 0-3  
Total-1,021-249-13,653  


Price Behavior

Price Behavior
Market Price$7.25 
Market Cap ($ Bil)0.0 
First Trading Date07/01/2015 
Distance from 52W High-23.4% 
   50 Days200 Days
DMA Price$5.63$6.84
DMA Trenddownup
Distance from DMA28.8%6.0%
 3M1YR
Volatility56.3%57.0%
Downside Capture-0.220.97
Upside Capture135.44135.43
Correlation (SPY)33.4%41.6%
TDOC Betas & Captures as of 4/30/2026

 1M2M3M6M1Y3Y
Beta0.621.301.471.531.921.52
Up Beta0.490.470.891.431.911.20
Down Beta4.782.732.631.622.311.26
Up Capture105%154%147%105%158%249%
Bmk +ve Days15223166141428
Stock +ve Days11202650112343
Down Capture105%116%143%173%166%113%
Bmk -ve Days4183056108321
Stock -ve Days10213672133400

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TDOC
TDOC9.4%56.9%0.36-
Sector ETF (XLV)7.9%15.4%0.3022.6%
Equity (SPY)29.0%12.5%1.8342.4%
Gold (GLD)39.8%27.0%1.229.6%
Commodities (DBC)50.6%18.0%2.21-4.7%
Real Estate (VNQ)13.0%13.5%0.6630.7%
Bitcoin (BTCUSD)-17.4%42.1%-0.3433.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TDOC
TDOC-46.0%63.4%-0.70-
Sector ETF (XLV)4.9%14.6%0.1631.8%
Equity (SPY)12.8%17.1%0.5946.5%
Gold (GLD)20.9%17.9%0.956.8%
Commodities (DBC)13.8%19.1%0.594.8%
Real Estate (VNQ)3.4%18.8%0.0838.9%
Bitcoin (BTCUSD)7.0%56.0%0.3427.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TDOC
TDOC-4.7%60.4%0.18-
Sector ETF (XLV)9.3%16.5%0.4627.6%
Equity (SPY)15.1%17.9%0.7235.8%
Gold (GLD)13.4%15.9%0.696.7%
Commodities (DBC)9.3%17.8%0.445.9%
Real Estate (VNQ)5.8%20.7%0.2422.6%
Bitcoin (BTCUSD)67.8%66.9%1.0714.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date4152026
Short Interest: Shares Quantity29.7 Mil
Short Interest: % Change Since 3312026-3.7%
Average Daily Volume4.0 Mil
Days-to-Cover Short Interest7.4 days
Basic Shares Quantity6.0 Mil
Short % of Basic Shares497.7%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/25/202615.1%10.3%18.7%
10/23/202510.0%1.6%-19.1%
7/29/2025-1.7%-7.6%2.8%
2/26/2025-13.6%-17.8%-22.1%
10/30/20241.6%6.5%35.2%
7/31/2024-8.9%-24.1%-24.7%
2/20/2024-23.7%-26.0%-24.8%
10/24/2023-3.9%-8.7%-5.9%
...
SUMMARY STATS   
# Positive886
# Negative101012
Median Positive8.1%8.4%4.6%
Median Negative-7.9%-12.2%-19.1%
Max Positive27.0%21.8%35.2%
Max Negative-23.7%-26.0%-30.8%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202604/30/202610-Q
12/31/202502/26/202610-K
09/30/202510/30/202510-Q
06/30/202507/30/202510-Q
03/31/202505/01/202510-Q
12/31/202402/27/202510-K
09/30/202410/31/202410-Q
06/30/202408/01/202410-Q
03/31/202404/26/202410-Q
12/31/202302/23/202410-K
09/30/202310/27/202310-Q
06/30/202307/28/202310-Q
03/31/202305/02/202310-Q
12/31/202203/01/202310-K
09/30/202211/02/202210-Q
06/30/202208/03/202210-Q

Recent Forward Guidance [BETA]

Latest: Q1 2026 Earnings Reported 4/29/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q2 2026 Revenue597.00 Mil611.50 Mil626.00 Mil0.4% RaisedGuidance: 609.00 Mil for Q1 2026
Q2 2026 Adjusted EBITDA55.00 Mil61.00 Mil67.00 Mil8.9% RaisedGuidance: 56.00 Mil for Q1 2026
Q2 2026 Net loss per share-0.3-0.25-0.2   
2026 Revenue2.48 Bil2.53 Bil2.58 Bil0 AffirmedGuidance: 2.53 Bil for 2026
2026 Adjusted EBITDA267.00 Mil286.50 Mil306.00 Mil-0.2% LoweredGuidance: 287.00 Mil for 2026
2026 Net loss per share-1.05-0.9-0.75   
2026 Free Cash Flow130.00 Mil150.00 Mil170.00 Mil0 AffirmedGuidance: 150.00 Mil for 2026

Prior: Q4 2025 Earnings Reported 2/25/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q1 2026 Revenue598.00 Mil609.00 Mil620.00 Mil-4.4% Lower NewActual: 637.00 Mil for Q4 2025
Q1 2026 Adjusted EBITDA50.00 Mil56.00 Mil62.00 Mil-31.3% Lower NewActual: 81.50 Mil for Q4 2025
2026 Revenue2.47 Bil2.53 Bil2.59 Bil0.2% Higher NewActual: 2.52 Bil for 2025
2026 Adjusted EBITDA266.00 Mil287.00 Mil308.00 Mil3.1% Higher NewActual: 278.50 Mil for 2025
2026 Free Cash Flow130.00 Mil150.00 Mil170.00 Mil-15.5% Lower NewActual: 177.50 Mil for 2025

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Divita, Charles IiiCHIEF EXECUTIVE OFFICERDirectSell31220265.4927,731152,2432,002,664Form
2Rodrigues, Fernando MPresident of BetterHelpDirectSell30320264.9825,086  Form
3Vandervoort, Adam CCHIEF LEGAL OFFICER, SECRETARYDirectSell30320265.1227,083138,584528,274Form
4Nueno, CarlosPresident, InternationalDirectSell30320265.1220,165103,184258,895Form
5Rodrigues, Fernando MPresident of BetterHelpDirectSell30320265.1216,31483,479128,365Form